Harlan Krumholz/LinkedIn
Dec 11, 2025, 12:50
Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
Harlan Krumholz, Harold H. Hines Jr. Professor at Yale University, shared on LinkedIn:
”Clinical trials rarely come with expiration dates.
Yet the patients we treat today are not the same as those studied 40 years ago.
New trials on beta blockers after myocardial infarction highlight how much cardiology has changed, and how slowly our evidence adapts.
This is not simply about one therapy.
It is about the half-life of evidence and the need for modern, pragmatic, real-time trials that keep pace with evolving practice.
I explored this in my latest piece.”
Read the full article here.
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers